571. “Real world” Impact of Letermovir for Prevention of Cytomegalovirus Infection in Hematopoietic-Cell Transplantation

BACKGROUND: Letermovir (LTM) was FDA-approved in 2017 for cytomegalovirus (CMV) prophylaxis in allogeneic hematopoietic cell transplant (HCT) patients. We evaluated the “real-world” impact of LTM in adult HCT recipients at the Mount Sinai Hospital in New York following addition of LTM to our formula...

Descripción completa

Detalles Bibliográficos
Autores principales: Loecher, Alyssa M, Yum, Kendra, Park, Daniel, Kim, Sara, Saunders-Hao, Patricia, Jakubowski, Rita, Keyzner, Alla, Steinberg, Amir, Rana, Meenakshi, Jacobs, Samantha E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778032/
http://dx.doi.org/10.1093/ofid/ofaa439.765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778032/
http://dx.doi.org/10.1093/ofid/ofaa439.765

Ejemplares similares